Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction
Kashani-Sabet, M.
Cancer 116(7): 1623-1625
2010
ISSN/ISBN: 0008-543X PMID: 20143442 DOI: 10.1002/cncr.24909
Accession: 056705088
Full Text Article emailed within 0-6 h
Payments are secure & encrypted
Related References
McClanahan, F.; Sharp, T.G.; Gribben, J.G. 2016: Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas? Haematologica 101(10): 1144-1158Ness, N.; Andersen, S.; Khanehkenari, M.Rakaee.; Nordbakken, C.V.; Valkov, A.; Paulsen, E-Elise.; Nordby, Y.; Bremnes, R.M.; Donnem, T.; Busund, L-Tove.; Richardsen, E. 2017: The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort Oncotarget 8(16): 26789-26801
Gao, Y.; Li, S.; Xu, D.; Chen, S.; Cai, Y.; Jiang, W.; Zhang, X.; Sun, J.; Wang, K.; Chang, B.; Wang, F.; Hong, M. 2017: Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma Chinese Journal of Cancer 36(1): 61
Kim, Y-June.; Park, S-Jung.; Broxmeyer, H.E. 2011: Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction Journal of Immunology 187(5): 2291-2301
Fouchard, M.; Jantzem, H.; Quere, G.; Descourt, R.; Robinet, G.; Poureau, P-Guillaume. 2019: Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer European Journal of Cancer 115: 107-110
Ren, Y.; Lv, Q.; Yue, W.; Liu, B.; Zou, Z. 2020: The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance and prognostic value: a study of 89 consecutive cases Melanoma Research 30(1): 85-101
Sun, X.; Roudi, R.; Dai, T.; Chen, S.; Fan, B.; Li, H.; Zhou, Y.; Zhou, M.; Zhu, B.; Yin, C.; Li, B.; Li, X. 2019: Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis Bmc Cancer 19(1): 558
Guan, X.; Wang, H.; Ma, F.; Qian, H.; Yi, Z.; Xu, B. 2016: The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines Medicine 95(11): E3134
Tay, W.Ting.; Fang, Y-Hsien.; Beh, S.Theng.; Liu, Y-Wen.; Hsu, L-Wei.; Yen, C-Jui.; Liu, P-Yen. 2020: Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro International Journal of Molecular Sciences 21(7)
Liu, Y.; Ma, J.; Yu, K.; Li, M.; Liu, F.; Yan, Q.; Wang, Z.; Guo, S. 2018: Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas Pathology Research and Practice 214(4): 507-512
Luo, M.; Fu, L. 2016: The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response Oncotarget 7(20): 29794-29803
Mikami, S.; Mizuno, R.; Kondo, T.; Shinohara, N.; Nonomura, N.; Ozono, S.; Eto, M.; Tatsugami, K.; Takayama, T.; Matsuyama, H.; Kishida, T.; Oya, M. 2019: Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma Cancer Science 110(6): 1820-1828
Qin, M.; Cao, Q.; Zheng, S.; Tian, Y.; Zhang, H.; Xie, J.; Xie, H.; Liu, Y.; Zhao, Y.; Gong, P. 2019: Discovery of [1,2,4]Triazolo[4,3- a]pyridines as Potent Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction Journal of Medicinal Chemistry 62(9): 4703-4715
Qin, M.; Cao, Q.; Wu, X.; Liu, C.; Zheng, S.; Xie, H.; Tian, Y.; Xie, J.; Zhao, Y.; Hou, Y.; Zhang, X.; Xu, B.; Zhang, H.; Wang, X. 2020: Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold European Journal of Medicinal Chemistry 186: 111856
Kawashita, S.; Aoyagi, K.; Yamanaka, H.; Hantani, R.; Naruoka, S.; Tanimoto, A.; Hori, Y.; Toyonaga, Y.; Fukushima, K.; Miyazaki, S.; Hantani, Y. 2019: Symmetry-based ligand design and evaluation of small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 interaction Bioorganic and Medicinal Chemistry Letters 29(17): 2464-2467
Santarpia, M.; González-Cao, Mía.; Viteri, S.; Karachaliou, N.; Altavilla, G.; Rosell, R. 2015: Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role Translational Lung Cancer Research 4(6): 728-742
Sugita, Y.; Furuta, T.; Ohshima, K.; Komaki, S.; Miyoshi, J.; Morioka, M.; Abe, H.; Nozawa, T.; Fujii, Y.; Takahashi, H.; Kakita, A. 2018: The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1 Neuropathology: Official Journal of the Japanese Society of Neuropathology 38(2): 125-134
Kim, S.; Kwon, D.; Koh, J.; Nam, S.Jeong.; Kim, Y.A.; Kim, T.Min.; Kim, C.Woo.; Jeon, Y.Kyung. 2020: Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified Virchows Archiv: An International Journal of Pathology 477(1): 131-142
Zhang, L.; Zhao, Y.; Tu, Q.; Xue, X.; Zhu, X.; Zhao, K-Nan. 2020: The role of programmed cell death ligand-1/ programmed cell death-1 (PD-L1/PD-1) in HPV-induced cervical cancer and potential for their use in blockade therapy Current Medicinal Chemistry 2020
Remon, J.; Chaput, N.; Planchard, D. 2016: Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancer Current Opinion in Oncology 28(2): 122-129